Stock comparison
Genmab A/S
ImmunityBio
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
IBRX
ImmunityBio
Market cap
$7.56B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | IBRX | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 31F | GMAB |
| Benjamin Graham | 64C | 45D | GMAB |
| Philip Fisher | 48D | 53C | IBRX |
| Peter Lynch | 25F | 52C | IBRX |
| Joel Greenblatt | 76B | 2F | GMAB |
| Charlie Munger | 68C | 53D | GMAB |
| Terry Smith | 71C | 55C | GMAB |
Side-by-side metrics
| Metric | GMAB | IBRX |
|---|---|---|
| Market cap | $16.5B | $7.56B |
| P/E (TTM) | 6.2x | - |
| EV/EBIT | 12.0x | - |
| ROIC (TTM) | 43.78% | -44.51% |
| Gross margin | 93.88% | 93.79% |
| Net margin | 18.23% | -6.06% |
| Revenue CAGR 5y | -18.45% | 2.32% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs -44.51%+198%
- Net margin18.23%vs -6.06%+103%
- Market cap$16.5Bvs $7.56B+54%
IBRX leads on
- P/E (TTM)-vs 6.2x+170%
- EV/EBIT-vs 12.0x+136%
- Revenue CAGR 5y2.32%vs -18.45%+108%
- Debt / Equity-vs 0.1x+106%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.